VKTX vs. GMAB, MRNA, VTRS, RDY, ASND, SRPT, PCVX, QGEN, ROIV, and RVMD
Should you be buying Viking Therapeutics stock or one of its competitors? The main competitors of Viking Therapeutics include Genmab A/S (GMAB), Moderna (MRNA), Viatris (VTRS), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Sarepta Therapeutics (SRPT), Vaxcyte (PCVX), Qiagen (QGEN), Roivant Sciences (ROIV), and Revolution Medicines (RVMD). These companies are all part of the "pharmaceutical products" industry.
Viking Therapeutics vs.
Genmab A/S (NASDAQ:GMAB) and Viking Therapeutics (NASDAQ:VKTX) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, institutional ownership, community ranking, media sentiment and profitability.
Genmab A/S currently has a consensus target price of $41.33, indicating a potential upside of 114.27%. Viking Therapeutics has a consensus target price of $97.67, indicating a potential upside of 233.56%. Given Viking Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Viking Therapeutics is more favorable than Genmab A/S.
Genmab A/S has a beta of 0.98, suggesting that its stock price is 2% less volatile than the S&P 500. Comparatively, Viking Therapeutics has a beta of 0.9, suggesting that its stock price is 10% less volatile than the S&P 500.
Viking Therapeutics received 462 more outperform votes than Genmab A/S when rated by MarketBeat users. Likewise, 80.00% of users gave Viking Therapeutics an outperform vote while only 63.12% of users gave Genmab A/S an outperform vote.
7.1% of Genmab A/S shares are owned by institutional investors. Comparatively, 76.0% of Viking Therapeutics shares are owned by institutional investors. 1.5% of Genmab A/S shares are owned by company insiders. Comparatively, 4.7% of Viking Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
In the previous week, Viking Therapeutics had 7 more articles in the media than Genmab A/S. MarketBeat recorded 17 mentions for Viking Therapeutics and 10 mentions for Genmab A/S. Viking Therapeutics' average media sentiment score of 1.00 beat Genmab A/S's score of 0.79 indicating that Viking Therapeutics is being referred to more favorably in the news media.
Genmab A/S has a net margin of 36.30% compared to Viking Therapeutics' net margin of 0.00%. Genmab A/S's return on equity of 16.78% beat Viking Therapeutics' return on equity.
Genmab A/S has higher revenue and earnings than Viking Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.
Summary
Viking Therapeutics beats Genmab A/S on 9 of the 17 factors compared between the two stocks.
Get Viking Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VKTX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Viking Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:VKTX) was last updated on 3/25/2025 by MarketBeat.com Staff
Buy VKTX Stock Free VKTX Stock Alerts